Suzhou Novoprotein Scientific Stock Price To Earnings To Growth
| 688137 Stock | 32.48 0.59 1.78% |
Suzhou Novoprotein Scientific fundamentals help investors to digest information that contributes to Suzhou Novoprotein's financial success or failures. It also enables traders to predict the movement of Suzhou Stock. The fundamental analysis module provides a way to measure Suzhou Novoprotein's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Suzhou Novoprotein stock.
Suzhou |
Suzhou Novoprotein Scientific Company Price To Earnings To Growth Analysis
Suzhou Novoprotein's PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.
| Competition |
Based on the latest financial disclosure, Suzhou Novoprotein Scientific has a Price To Earnings To Growth of 0.0 times. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all China stocks average (which is currently at 0.0).
Did you try this?
Run Portfolio Manager Now
Portfolio ManagerState of the art Portfolio Manager to monitor and improve performance of your invested capital |
| All Next | Launch Module |
Suzhou Fundamentals
| Return On Equity | -0.0099 | ||||
| Return On Asset | -0.0228 | ||||
| Profit Margin | (0.16) % | ||||
| Operating Margin | 0.58 % | ||||
| Current Valuation | 1.68 B | ||||
| Shares Outstanding | 70.18 M | ||||
| Shares Owned By Insiders | 72.60 % | ||||
| Shares Owned By Institutions | 5.01 % | ||||
| Price To Book | 1.07 X | ||||
| Price To Sales | 16.94 X | ||||
| Revenue | 153.19 M | ||||
| Gross Profit | 228.37 M | ||||
| EBITDA | (71.71 M) | ||||
| Net Income | 12.84 M | ||||
| Total Debt | 11.08 M | ||||
| Book Value Per Share | 29.05 X | ||||
| Cash Flow From Operations | 69.16 M | ||||
| Earnings Per Share | (0.31) X | ||||
| Number Of Employees | 579 | ||||
| Beta | 2.14 | ||||
| Market Capitalization | 2.28 B | ||||
| Total Asset | 2.3 B | ||||
| Retained Earnings | 149.52 M | ||||
| Working Capital | 2.02 B | ||||
| Annual Yield | 0.02 % | ||||
| Net Asset | 2.3 B | ||||
| Last Dividend Paid | 0.5 |
About Suzhou Novoprotein Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Suzhou Novoprotein Scientific's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Suzhou Novoprotein using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Suzhou Novoprotein Scientific based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Suzhou Stock
Suzhou Novoprotein financial ratios help investors to determine whether Suzhou Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Suzhou with respect to the benefits of owning Suzhou Novoprotein security.